A lot of fundamental research takes place in the Dutch University medical Centers. This research regularly leads to promising discoveries that may lead to new therapies. Before the efficacy of such a potential treatment can be tested in a large clinical study, it is necessary to test the safety and feasibility in a small group patients. This translational research requires high demands and is therefore time-consuming, labor-intensive and expensive. Via several programs ZonMw enables those first steps into the clinic.
GloPID-R is pleased to welcome the Netherlands Organisation for Health Research and Development (ZonMw), represented by Suzanne Verver, into the network. GloPID-R is a unique international network of major research funding organizations. The network of 27 countries facilitates a rapid and effective research response to infectious disease outbreaks.
KNAW (Royal Netherlands Academy of Arts and Sciences), NWO (Netherlands Organisation for Scientific Research) and ZonMw (Netherlands Organisation for Health Research and Development) will sign the San Francisco Declaration on Research Assessment (DORA) on 18 April.
On April 1st 2019 the kick-off meeting of the European public-private partnership VALUE-Dx took place. This European-wide approach aims to generate evidence on the medical, economic, and public health value of diagnostics in tackling antimicrobial resistance (AMR). As a member of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), ZonMw participates in this consortium.
17 researchers who have recently received their PhDs can do their research at foreign research institutes thanks to a Rubicon grant from NWO. They will investigate, amongst other things, artificial intelligence for improved ultrasonography, Imaging muscle function in ALS patients, Printing living tissue through protective cell coating and new blood vessel formation.
While the pharmaceutical, medical technologies, chemical, cosmetics and food industries are increasingly seeking solutions to improve for example their prediction of clinical efficacy and/or risk and safety assessments without the use of animals, the solutions are still insufficient;
Societal demand for animal-free testing is increasing and there is a need for new innovations to improve human health, a stimulation of this research field is therefore needed;